PMDA drug package insert
ゲフィチニブ錠250mg「JG」
PMDA Prescription drug · 日本ジェネリック株式会社 · package insert Nov 4, 2025
Key facts
| Brand names | ゲフィチニブ錠250mg「JG」 |
|---|---|
| Nonproprietary names | ゲフィチニブ |
| Companies | 製造販売元／日本ジェネリック株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗悪性腫瘍剤／上皮成長因子受容体（EGFR）チロシンキナーゼ阻害剤 |
| Therapeutic category codes | 874291 |
| YJ codes | 4291013F1043 |
| Approval numbers | 23100AMX00235000 |
| Package insert edition | 第3版 |
| Package insert date | Nov 4, 2025 |
| PMDA document key | 580591_4291013F1043_1 |
| PMDA company code | 580591 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: